Continuous Glucose Monitor Benefits Type Two Diabetic Issues Control, Some New Researches Show

Press release: 01 August, 2021: CGM (continuous glucose monitoring) is a popular treatment option for diabetics with type 1 diabetes. Now, two new research findings suggest CGM might be a worthwhile option to add to the treatment plans of people with type 2 diabetes who use insulin.

In one study published June 2nd, 2021 in the Journal of the American Medical Association (JAMA) researchers observed that people with type 2 diabetes who are using insulin could reap more advantages from this device than they would from a traditional blood glucose monitor, for which they periodically prick their skin to check their blood sugar levels.

The effectiveness of two monitoring devices was assessed on 175 people suffering from type 2 diabetes who were taking insulin. Participants' average hemoglobin A1C levels which show the average blood sugar levels for around three months, was at 9.1 percent. Type 2 diabetes can be indicated by readings above 6.5 percent. Readings above 8 percent indicate that blood sugar levels can be controlled better and are associated with increased complications.

When the study, researchers randomly assigned 116 participants to utilize CGMs and 56 who used traditional monitors of blood glucose over eight months. They recorded an average A1C level of 8.4 percent when using traditional monitors for blood glucose by the time they completed their following-up.

One of the reasons for the disparity in the results could be due to the way often patients test their blood by using their own instruments. The continuous glucose monitors in the study checked the levels of blood sugar every 5 minutes, without any intervention required by the patients, patients using traditional blood glucose monitors were able to check their levels just 1.5 times a day , on average.

Roy Beck, MD, PhD is a coauthor and the president of Jaeb Center for Health Research Foundation, Tampa, Florida. He says that glucose levels can fluctuate a lot during the day, particularly in patients with insulin dependence. The one or two measures are not always representative of glucose levels at different times of the day.

"So those who use the blood glucose monitor one or two times per day often have no idea that their blood sugar levels could be significantly higher after an eating event," Dr. Beck states.

Clinical Trial Shows the benefits of Continuous Glucose Monitoring

The patients studied in the study used basal insulin, dosages made to maintain steady blood sugar levels throughout the day and at night however, they did not use prandial insulin. These are fast-acting doses taken before meals to prevent rapid fluctuations in blood sugar levels after eating.

The study's drawbacks are that the results could not be relevant to diabetics of type 2 who take both basal and prandial insulin doses. The study provided greater assistance and supervision to patients than they would get in real life. It is possible that the results could differ for those who utilize CGM in the real world, that is, not in the clinical setting. Navigate to this website to find out a full article on glucose meter without blood.

Another study has shown that CGM could be beneficial for patients with type 2 diabetes who are using insulin to control their blood sugar. A different study, which was released in JAMA on June 2, 2021 looked at the levels of blood sugar at the time of and after individuals with diabetes began taking CGM. The study found CGM was beneficial in both types one and type two. The study looked at data from 3,806 patients who began the use of CGM and 37,947 people who did not -- all of whom were treated at Kaiser Permanente facilities in Northern California between 2014 and the year 2019.

CGM can also be beneficial to the type 2 diabetes in a'real-world' study

In the group of CGM initiators, average A1C levels dropped from 8.2 percent prior to the initiation date to 7.64 percent 12 months afterward. Over a similar 24-month window the non-initiators' average A1C levels fall much more, from 8.27 percent to 8.18 percent.

In addition, the proportion of people who were initiators with type 2 diabetes who had A1C levels less than 7 percent, which is the threshold at which diabetes is thought to be well controlled in the first place, jumped from 19.7 percent in the 12 months prior to beginning to 32.2 percent after 12 months. However, the percentage of non-initiators with A1C levels below 7 percent increased from 18.0 percent to 20.3 percent over the same 24-month window.

CGM was also linked to an improvement in hypoglycemia (dangerously low blood sugar levels) and hyperglycemia (dangerously high blood sugar levels) among diabetics of type 2.

This study has the advantage of being based upon real-world patient experiences. However, one drawback of the study is that it's not a controlled trial like the study mentioned previously, and it's possible there are some unidentified variations between initiators and those who didn't which could explain their differing results.

Contact information:

Website: https://www.mypainpro.com/